Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 7/20 | 0.52 |
| ▸ | QPCT | Q16769 | 2/20 | 0.51 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.48 |
| ▸ | GRK2 | P25098 | 3/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2315631 | 0.91 | SCD (0.58) | SCDGRK2MMP13 | |
| SCHEMBL2315711 | 0.89 | SCD (0.63) | SCDGRK2MMP13 | |
| SCHEMBL2312920 | 0.87 | MMP13 (0.60) | SCDQPCTGRK2MMP13 | |
| SCHEMBL2318321 | 0.85 | SCD (0.61) | SCDGRK2MMP13 | |
| SCHEMBL2317979 | 0.82 | L3MBTL1 (0.51) | SCDGRK2 | |
| SCHEMBL2315222 | 0.82 | GRK2 (0.50) | SCDGRK2MMP13 | |
| SCHEMBL2316647 | 0.81 | MMP13 (0.52) | SCDQPCTQPCTLGRK2MMP13 | |
| SCHEMBL2315109 | 0.80 | PDE5A (0.50) | SCDQPCTQPCTLGRK2MMP13 | |
| SCHEMBL2312640 | 0.80 | SCD (0.63) | SCD | |
| SCHEMBL2314365 | 0.79 | SCD (0.83) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350029-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010056230-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20090105283-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20080255161-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255161-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, ECHS1 | SCD 1/4885QPCT 332/4885QPCTL 1583/4885 |
| US-20090105283-A1 | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, ECHS1 | SCD 1/4885QPCT 332/4885QPCTL 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.